The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer.
AffiliationDepartment of Radiation Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
MetadataShow full item record
AbstractPatients with localized muscle-invasive bladder cancer (MIBC) can choose to undergo either neoadjuvant chemotherapy followed by radical cystectomy or radiation therapy-based bladder preservation treatment modality with subsequent close cystoscopic surveillance with salvage cystectomy reserved for patients with evidence of local disease recurrence. At the present time, the decision regarding bladder-directed local therapy for MIBC is based on physicians' and patients' preferences, and does not take into account tumor biology. Predictive biomarkers, once validated, could offer a more patient-centered and biology-driven selection of bladder-directed therapies.
CitationThe role of biomarkers in bladder preservation management of muscle-invasive bladder cancer. 2018, World J Urol
JournalWorld Journal of Urology